Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00109161|
Recruitment Status : Completed
First Posted : April 25, 2005
Last Update Posted : August 5, 2008
PDL BioPharma, Inc.
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||No date given|
|Study Completion Date :||October 2006|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Erratum in: Lancet Neurol. 2010 Aug;9(8):759. Wadinger, K [corrected to Wandinger, K].